若您需要咨询产品或有任何技术问题,请通过官方电话 400 885 9050 或邮箱 info.cn@stemcell.com 与我们联系

Videos and Webinars

视图 %1及以上 列表

338 项目

设置降序方向
  1. hPSC Lines for Cell Therapies - Panel Discussion
    Nature Research Round Table: hPSC Lines for Cell Therapies - Panel Discussion In this panel discussion led by Dr. Christine Mummery from the Leiden University Medical Center, keynote speakers respond to questions from the forum and evaluate consensuses around topics raised in the previous talks.

    This panel discussion was part of a Round Table series titled “Challenges in Ensuring hPSC Quality”, hosted in partnership with Nature Research. Global experts gathered at the Springer Nature headquarters in London, UK, to tackle some of the most pertinent issues impacting the use of human pluripotent stem cells (hPSCs), ranging from fundamental biology research to therapeutic applications. Explore the full series here.
  2. Human Pluripotent Stem Cell Lines as Disease Models
    Nature Research Round Table: Human Pluripotent Stem Cell Lines as Disease Models Dr. Christine Mummery from the Leiden University Medical Center discusses the use of human pluripotent stem cells (hPSCs) for disease modeling and what standards are required; including for genome integrity, routine checks, and journal requirements.

    This presentation was part of a Round Table series titled “Challenges in Ensuring hPSC Quality”, hosted in partnership with Nature Research. Global experts gathered at the Springer Nature headquarters in London, UK, to tackle some of the most pertinent issues impacting the use of human pluripotent stem cells (hPSCs), ranging from fundamental biology research to therapeutic applications. Explore the full series here.

    Note: Some original data from this presentation has been omitted to abide by copyright rules.
  3. Parkinson's Disease Therapy with Human Embryonic Stem Cells
    Nature Research Round Table: Parkinson's Disease Therapy with Human Embryonic Stem Cells Dr. Malin Parmar from Lund University talks about her work on cell-based therapies to treat Parkinson’s disease, as well as regulatory, safety, and efficacy requirements for the clinic. This presentation and the following Q&A session were moderated by Dr. Christine Mummery from the Leiden University Medical Center.

    This presentation was part of a Round Table series titled “Challenges in Ensuring hPSC Quality”, hosted in partnership with Nature Research. Global experts gathered at the Springer Nature headquarters in London, UK, to tackle some of the most pertinent issues impacting the use of human pluripotent stem cells (hPSCs), ranging from fundamental biology research to therapeutic applications. Explore the full series here.

    Note: Some original data from this presentation has been omitted to abide by copyright rules.
  4. Retinal Cell Therapy Using Human Embryonic Stem Cells
    Nature Research Round Table: Retinal Cell Therapy Using Human Embryonic Stem Cells Dr. Peter Coffey from University College London shares his work with the London Project to Cure Blindness, which resulted in the first clinical stem cell trial to treat blindness, and discusses cell quality requirements for clinical trials. This presentation and the following Q&A session were moderated by Dr. Christine Mummery from the Leiden University Medical Center.

    This presentation was part of a Round Table series titled “Challenges in Ensuring hPSC Quality”, hosted in partnership with Nature Research. Global experts gathered at the Springer Nature headquarters in London, UK, to tackle some of the most pertinent issues impacting the use of human pluripotent stem cells (hPSCs), ranging from fundamental biology research to therapeutic applications. Explore the full series here.

    Note: Some original data from this presentation has been omitted to abide by copyright rules.
  5. Best Practices for the QC of Genome-Edited hPSC Lines - Panel Discussion
    Nature Research Round Table: Best Practices for the QC of Genome-Edited hPSC Lines - Panel Discussion In this panel discussion led by Dr. Peter Andrews from the University of Sheffield and Dr. Martin Pera from the Jackson Laboratory, keynote speakers respond to questions from the forum and evaluate consensuses around topics raised in the previous talks.

    This panel discussion was part of a Round Table series titled “Challenges in Ensuring hPSC Quality”, hosted in partnership with Nature Research. Global experts gathered at the Springer Nature headquarters in London, UK, to tackle some of the most pertinent issues impacting the use of human pluripotent stem cells (hPSCs), ranging from fundamental biology research to therapeutic applications. Explore the full series here.
  6. Genomic Integrity of Human Pluripotent Stem Cells
    Nature Research Round Table: Genomic Integrity of Human Pluripotent Stem Cells Dr. Martin Pera from the Jackson Laboratory and International Stem Cell Initiative (ISCI) discusses the biological effects of recurrent genetic variants that arise in human pluripotent stem cells (hPSCs) in culture and during differentiation. This presentation and the following Q&A session were moderated by Dr. Peter Andrews from the University of Sheffield.

    This presentation was part of a Round Table series titled “Challenges in Ensuring hPSC Quality”, hosted in partnership with Nature Research. Global experts gathered at the Springer Nature headquarters in London, UK, to tackle some of the most pertinent issues impacting the use of human pluripotent stem cells (hPSCs), ranging from fundamental biology research to therapeutic applications. Explore the full series here.

    Note: Some original data from this presentation has been omitted to abide by copyright rules.
  7. The Process of Human Pluripotent Stem Cell Adaptation
    Nature Research Round Table: The Process of Human Pluripotent Stem Cell Adaptation Dr. Ivana Barbaric from the Center for Stem Cell Biology at the University of Sheffield talks about culture-acquired genetic changes in human pluripotent stem cells (hPSCs), ways of detecting them, and implications for research and downstream clinical therapies. This presentation and the following Q&A session were moderated by Dr. Peter Andrews from the University of Sheffield.

    This presentation was part of a Round Table series titled "Challenges in Ensuring hPSC Quality", hosted in partnership with Nature Research. Global experts gathered at the Springer Nature headquarters in London, UK, to tackle some of the most pertinent issues impacting the use of human pluripotent stem cells (hPSCs), ranging from fundamental biology research to therapeutic applications. Explore the full series here.

    Note: Some original data from this presentation has been omitted to abide by copyright rules.
  8. Genome Editing in Human Pluripotent Stem Cells
    Nature Research Round Table: Genome Editing in Human Pluripotent Stem Cells Dr. Ludovic Vallier from the Wellcome Trust Sanger Institute discusses considerations for genome editing in human pluripotent stem cells (hPSCs). Dr. Vallier is involved at the Cambridge Biomedical Research Center Core Facility, whose services include providing genome-edited iPS cell lines for disease modeling and developing approaches for cell-based therapies. This presentation and the following Q&A session were moderated by Dr. Alex Alderton from the Wellcome Trust Sanger Institute.

    This presentation was part of a Round Table series titled “Challenges in Ensuring hPSC Quality”, hosted in partnership with Nature Research. Global experts gathered at the Springer Nature headquarters in London, UK, to tackle some of the most pertinent issues impacting the use of human pluripotent stem cells (hPSCs), ranging from fundamental biology research to therapeutic applications. Explore the full series here.

    Note: Some original data from this presentation has been omitted to abide by copyright rules.
  9. Identifying Acquired and Background Genetic Variants in Human Pluripotent Stem Cells
    Nature Research Round Table: Identifying Acquired and Background Genetic Variants in Human Pluripotent Stem Cells Dr. Florian Merkle from the University of Cambridge talks about the implications of quality control during gene editing, in particular genetic variants that arise during routine culture and genetic variants that might have been acquired during the process of gene editing. This presentation and the following Q&A session were moderated by Dr. Alex Alderton from the Wellcome Trust Sanger Institute.

    This presentation was part of a Round Table series titled “Challenges in Ensuring hPSC Quality”, hosted in partnership with Nature Research. Global experts gathered at the Springer Nature headquarters in London, UK, to tackle some of the most pertinent issues impacting the use of human pluripotent stem cells (hPSCs), ranging from fundamental biology research to therapeutic applications. Explore the full series here.
  10. Defining and Maintaining Pluripotency & hPSC Line Registration and Banking - Panel Discussion
    Nature Research Round Table: Defining and Maintaining Pluripotency & hPSC Line Registration and Banking - Panel Discussion In this panel discussion led by Dr. Ludovic Vallier from the Wellcome Trust Sanger Institute and Dr. Joanne Mountford from the University of Glasgow, keynote speakers respond to questions from the forum and evaluate consensuses on topics raised in the previous talks.

    This panel discussion was part of a Round Table series titled “Challenges in Ensuring hPSC Quality”, hosted in partnership with Nature Research. Global experts gathered at the Springer Nature headquarters in London, UK, to tackle some of the most pertinent issues impacting the use of human pluripotent stem cells (hPSCs), ranging from fundamental biology research to therapeutic applications. Explore the full series here.
  11. Standards for Pluripotent Stem Cell Banking
    Nature Research Round Table: Standards for Pluripotent Stem Cell Banking Dr. Glyn Stacey, Director of the International Stem Cell Banking Initiative (ISCBI), discusses standards for pluripotent stem cell (PSC) banking with a focus on scientific challenges for PSCs, standardization of ethics, the role of stem cell biobanks, and best practices for cell therapy. This presentation and the following Q&A session were moderated by Dr. Joanne Mountford from the University of Glasgow.

    This presentation was part of a Round Table series titled “Challenges in Ensuring hPSC Quality”, hosted in partnership with Nature Research. Global experts gathered at the Springer Nature headquarters in London, UK, to tackle some of the most pertinent issues impacting the use of human pluripotent stem cells (hPSCs), ranging from fundamental biology research to therapeutic applications. Explore the full series here.
  12. HLA Typing Considerations for Human Pluripotent Stem Cell Banking
    Nature Research Round Table: HLA Typing Considerations for Human Pluripotent Stem Cell Banking Dr. David Turner from the Scottish National Blood Transfusion Service discusses immunological considerations around banking of human pluripotent stem cell (hPSC) lines for use in clinical trials. Dr. Turner’s work at the Histocompatibility and Immunogenetics (H&I) Laboratory involves donor-patient HLA-matching for clinical transplants. This presentation and the following Q&A session were moderated by Dr. Joanne Mountford from the University of Glasgow.

    This presentation was part of a Round Table series titled “Challenges in Ensuring hPSC Quality”, hosted in partnership with Nature Research. Global experts gathered at the Springer Nature headquarters in London, UK, to tackle some of the most pertinent issues impacting the use of human pluripotent stem cells (hPSCs), ranging from fundamental biology research to therapeutic applications. Explore the full series here.

    Note: Some original data from this presentation has been omitted to abide by copyright rules.
每页
Copyright © 2025 by STEMCELL Technologies. All rights reserved.